Showing 6791-6800 of 8840 results for "".
- Inaugural ElderDerm Conference Hosted by GWhttps://practicaldermatology.com/news/inaugural-elderderm-conference-hosted-gw/2467204/The inaugural ElderDerm Conference was held June 6 in Washington, DC, hosted by the GW Department of Dermatology. Co-Director Adam Friedman, MD, a Practical DermatologyÒ Editorial Board member, presented two talks: “Hair Loss in the Elderly: Considerations and Therapeutic Approaches” and
- Erenumab Associated with Reduced Rosacea-associated Flushing, Chronic Erythemahttps://practicaldermatology.com/news/erenumab-associated-reduced-rosacea-associated-flushing-chronic-erythema/2467166/Erenumab, an anti–calcitonin gene-related peptide (CGRP)-receptor monoclonal antibody, was shown in new research to be effective at reducing the number of days with rosacea-associated erythema and flushing in treated patients.
- Study: Oral Minoxidil Not Superior to Topical Minoxidilhttps://practicaldermatology.com/news/non-oral-and-topical-minoxidil/2467152/Daily oral minoxidil, 5 mg was not superior to topical minoxidil, 5%, in a population of male patients with alopecia according to a new study in JAMA Dermatology. "There has been increased interest in low-dose oral minoxidil for androgenetic alopecia (AGA) treatment," the autho
- Link Between UV Exposure and Cutaneous Angiosarcoma Incidencehttps://practicaldermatology.com/news/link-between-uv-exposure-and-cutaneous-angiosarcoma-incidence/2467139/Ambient ultraviolet radiation (UVR) was associated with a higher incidence of cutaneous angiosarcoma (cAS), an aggressive lymphatic/vascular endothelial-based cancer. Researchers publishing the findings in a research letter in Journal of the American Academy of Dermatology (JAAD)<
- FDA Approves Gel for Axillary Hyperhidrosishttps://practicaldermatology.com/news/fda-approves-gel-axillary-hyperhidrosis/2467109/The US Food and Drug Administration (FDA) has approved a new prescription gel used to treat axillary hyperhidrosis (excessive underarm sweating) in adults and children 9 and older, manufacturer Botanix Pharmaceuticals announced. Sofdra (sofpironium) is the first chemical entity approved b
- New siRNA Therapy for Benign Lesions Could Reduce Risk for Future Cancerhttps://practicaldermatology.com/news/new-sirna-therapy-benign-lesions-precursor-cancer/2467089/Researchers have developed a novel genetic therapy for reversing the formation of giant moles in patients with congenital melanocytic naevus syndrome (CMN), thereby also reducing their risk for developing melanoma later on. The therapy for this rare condition works by suppressing the NRAS
- Report: Aesthetic Lasers Market to Surge 16.6% Annually Through 2032https://practicaldermatology.com/news/report-aesthetic-lasers-market-surge-166-annually-through-2032/2467086/Markets for aesthetic lasers are projected to $5.392 billion by 2032, according to a new report fro
- Study: Advanced AI Enhances Melanoma Detectionhttps://practicaldermatology.com/news/study-advanced-ai-enhances-melanoma-detection/2467071/A new study suggests a novel deep-learning model based on diagnostic data may help harness the power of neural networks and artificial intelligence (AI) to more accurately diagnose melanoma.
- Survey: 43% With Acne Worry They'll Never Have Clear Skinhttps://practicaldermatology.com/news/survey-43-acne-worry-theyll-never-have-clear-skin/2467063/Ninety percent of acne sufferers experience daily insecurities related to their acne, and 43% worry they will never have clear skin, according to a new survey conducted by Cutera, Inc. June is Acne Awareness Month, and Cutera said in a press release that the findings of the survey “highli
- Neoadjuvant Ipilimumab and Nivolumab Therapy Improves Survival in Stage III Melanomahttps://practicaldermatology.com/news/neoadjuvant-ipilimumab-and-nivolumab-therapy-improves-survival-stage-iii-melanoma/2467064/New phase 3 study results from the NADINA study suggest that neoadjuvant (neoadj) therapy with ipilimumab (IPI) and nivolumab (NIVO) followed by response-driven adjuvant therapy was associated with increased event-free survival (EFS) in patients with macroscopic stage III melanoma. The re